SwitzerReport

Independent. Trusted. Proven.

Investing

Investment analysis, share recommendations, and market insights.

4 cancer fighting stocks — Investing
Premium

4 cancer fighting stocks

The ASX has a burgeoning life sciences cohort doing great work in a range of major diseases. Here are four interesting cancer fighters.

James Dunn · July 29, 2024
“HOT” stock: Audinate (ASX:AD8) — Investing
Premium

“HOT” stock: Audinate (ASX:AD8)

In our “HOT” stock column, Michael Wayne, Managing Director of Medallion Financial Group, says that for investors who feared they may have missed their chance with Audinate, the current price may present an attractive opportunity to begin accumulating a high-quality growth business during a pull-back.

Maureen Jordan · July 25, 2024
Should we dump HNDQ and tech stocks? — Investing
Premium

Should we dump HNDQ and tech stocks?

HNDQ and going long the Nasdaq’s top stocks has been a rewarding play but is it time to take profit and look for another play that will be helped by the rotation out of big tech into smaller growth stocks? As one investing door closes, another one opens, so let’s go looking for a good door for the year ahead.

Peter Switzer · July 22, 2024
“HOT” stock: CSL — Investing
Premium

“HOT” stock: CSL

For our “HOT” stock today, Raymond Chan, Head of Asian Desk at Morgans, looks at the good news associated with CSL.

Maureen Jordan · July 22, 2024
Earnings surprise 2024 — Investing
Premium

Earnings surprise 2024

Four situations where the news flow from the companies so far has generally been fairly good; and where a further positive surprise is not out of the question.

James Dunn · July 22, 2024

You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.